Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a medical research study designed to look at the safety and efficacy of 30-day course
of fidaxomicin for treatment of recurrent CDI (Clostridium difficile Infection). CDI is an
infection that results when the normal flora (resident bacteria) of the colon is
substantially altered by antibiotic treatment. The decrease in this normal flora allows for
the growth of the C. difficile bacteria. Fidaxomicin is an antibiotic which is approved by
Health Canada for treatment of CDI. Only patients with a primary case of CDI or 1st episode
of recurrent CDI have been studied using a 10-day course of fidaxomicin.